Arctic Bioscience announces private placement and intention to list on Euronext Growth Oslo
The Norwegian biotechnology company developing a novel treatment for mild-to-moderate psoriasis, has engaged ABG Sundal Collier ASA and DNB Markets as joint global coordinators and joint bookrunners to advise on and effect a contemplated private placement raising gross proceeds of NOK 250 million and admission to trading of the Company’s shares on Euronext Growth Oslo.NOT FOR DISTRIBUTION, RELEASE OR REPUBLICATION, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE